BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Immune Design Corporation 

1102 Columbia Street
Suite 104
Seattle  Washington  98104  U.S.A.
Phone: n/a Fax: n/a


SEARCH JOBS




Industry
Biotechnology

Segment
Start Up





 Company News
Immune Design Corporation (IMDZ) Announces Filing Of New Lawsuit By Theravectys SA 7/28/2014 7:55:18 AM
THERAVECTYS Files Suit In The U.S. Against Immune Design Corporation (IMDZ) 7/25/2014 9:10:42 AM
Seattle Biotech Immune Design Corporation (IMDZ) Prices IPO At $12 Per Share, The Low End Of The Range 7/24/2014 9:06:27 AM
Seattle's Immune Design Corporation (IMDZ) Files For $60 Million IPO 6/26/2014 4:00:44 PM
Immune Design Corporation Announces Treatment Of First Patient In Phase 1 Clinical Trial Of LV305 Immuno-Oncology Agent 6/5/2014 8:38:55 AM
Immune Design Corporation's GLAAS™ Discovery Platform Used In MEDI7510 Phase 1 Trial For Respiratory Syncytial Virus 5/27/2014 9:29:32 AM
Immune Design Corporation Appoints Franklin M. Berger To Board Of Directors 3/18/2014 6:34:05 AM
Immune Design Corporation Announces Treatment Of First Patient In Phase 1 Clinical Trial Of ID-G305 Cancer Immunotherapy Agent 2/27/2014 9:25:31 AM
Immune Design Corporation To Present At Upcoming Investor Conferences In February 2/3/2014 8:57:38 AM
Immune Design Corporation Announces Treatment Of First Patient In Phase 1 Clinical Trial Of ID-G100, An Investigational Immuno-Oncology Agent 1/27/2014 9:55:18 AM
123